583 related articles for article (PubMed ID: 30231931)
1. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.
Ye H; Li Z; Liu K; Zhang F; Cheng Z
Medicine (Baltimore); 2021 Jun; 100(23):e25709. PubMed ID: 34114981
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
Li L; Zhang H; Xie Y; Su N; Su S; Zhang X; Cen W
Comput Math Methods Med; 2022; 2022():1475871. PubMed ID: 35251294
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Wang ZM; Zhang SL; Yang H; Zhuang RY; Guo X; Tong HX; Zhang Y; Lu WQ; Zhou YH
Cancer Med; 2020 May; 9(10):3344-3352. PubMed ID: 32181596
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated
Li T; Chang K; Qiu X; Lai Z; Luo Y; Chen J; Lv W; Lin Z; Pei X; Wu X; Wang X
Transl Lung Cancer Res; 2023 Jun; 12(6):1256-1263. PubMed ID: 37425401
[TBL] [Abstract][Full Text] [Related]
6. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S; Wang H
Drug Des Devel Ther; 2023; 17():3429-3437. PubMed ID: 38024530
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract][Full Text] [Related]
8. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism.
Lu Y; Han X; Zhang H; Zheng L; Li X
Eur J Pharmacol; 2024 Jul; 975():176639. PubMed ID: 38729415
[TBL] [Abstract][Full Text] [Related]
10. Effective Treatment of Anlotinib Combined With Chemotherapy in Children With Desmoplastic Small Round Cell Tumor: A Case Series in a Single-center and Literature Review.
Jing XY; Shen CQ; He GQ; Xu RR; Gao J; Guo X
J Pediatr Hematol Oncol; 2024 Apr; 46(3):159-164. PubMed ID: 38408140
[TBL] [Abstract][Full Text] [Related]
11. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.
Meng Q; Han J; Wang P; Jia C; Guan M; Zhang B; Zhao W
J Bone Oncol; 2024 Apr; 45():100594. PubMed ID: 38532893
[TBL] [Abstract][Full Text] [Related]
12. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma.
Lin X; Pan F; Abudoureyimu M; Wang T; Hao L; Wang R
Biochem Biophys Res Commun; 2024 Jan; 690():149247. PubMed ID: 38000292
[TBL] [Abstract][Full Text] [Related]
13. Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.
Lu J; Shi Q; Zhang L; Wu J; Lou Y; Qian J; Zhang B; Wang S; Wang H; Zhao X; Han B
Front Oncol; 2019; 9():886. PubMed ID: 31572680
[TBL] [Abstract][Full Text] [Related]
14. Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report.
Mao J; Ye W; Wu D; Liu J; Li T; Ma W; Zhou Y
Front Pharmacol; 2023; 14():1166809. PubMed ID: 37521461
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer.
Liu B; Peng Y; Su Y; Diao C; Qian J; Zhan X; Cheng R
Anticancer Drugs; 2024 Jun; ():. PubMed ID: 38820067
[TBL] [Abstract][Full Text] [Related]
16. A Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib?
Alkaissi H; Pacak K
J Endocr Soc; 2024 May; 8(7):bvae092. PubMed ID: 38799768
[No Abstract] [Full Text] [Related]
17. The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia.
Yang L; Zhao Q; Yu J; Wang L
J Transl Med; 2023 Oct; 21(1):683. PubMed ID: 37779202
[No Abstract] [Full Text] [Related]
18. Anlotinib as a molecular targeted therapy for tumors.
Gao Y; Liu P; Shi R
Oncol Lett; 2020 Aug; 20(2):1001-1014. PubMed ID: 32724339
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
Chen XZ
JAMA Oncol; 2019 Jan; 5(1):116-117. PubMed ID: 30489609
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
